The latest pharmacotherapeutic options for the treatment of IgA nephropathy in the pediatric population
The higher disease activity and longer life expectancy in pediatric patients create a critical need for the evaluation of modern therapies in children with IgAN. Thus, it is crucial to prioritize pediatric clinical trials and to focus on removing the barriers that limit their implementation.
Authors
- Jakub Zieg
Institutions
- Charles University (CZ)
- University Hospital in Motol (CZ)
Publication Details
- Journal
- Expert Opinion on Pharmacotherapy
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1080/14656566.2026.2620099
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00